Which genes does Bosutinib target?

Bosutinib/Bosutinib (Bosutinib) is an oral small molecule tyrosine kinase inhibitor mainly used for the treatment of chronic myelogenous leukemia (CML). Its core mechanism of action is to selectively inhibit the tyrosine kinase activity of BCR-ABL fusion protein. BCR-ABL is an abnormal fusion gene product produced by the Philadelphia chromosome (Ph chromosome), which can continuously activate downstream signaling pathways, including RAS/MAPK, PI3K/AKT and STAT pathways, thereby promoting abnormal proliferation and survival of leukemia cells. By inhibiting BCR-ABL, bosutinib can directly interfere with the main driving mechanism of leukemia cells and achieve anti-tumor effects.

In addition toBCR-ABL, bosutinib also has a certain inhibitory effect on SRC family kinases. SRC family kinases are widely involved in cell proliferation, migration and angiogenesis processes, and are of great significance to the regulation of the tumor microenvironment. Therefore, bosutinib can also affect the growth of leukemia and some tumor cells through SRC inhibition to a certain extent. In addition, the sensitivity of bosutinib to ABL mutations also varies. Some common drug-resistant mutations may reduce drug activity, while some mutations can still be inhibited by bosutinib, which is also its important value in later-line treatment.

The multi-target characteristics of bosutinib not only play a role in chronic myelogenous leukemia, but also provide a theoretical basis for the study of other leukemia subtypes. It achieves cell cycle arrest, induces apoptosis and inhibits abnormal proliferation by blocking abnormal kinase signals. It also shows potential effects on specific subpopulations of cancer stem cells in experimental models. For patients, drug strategies that precisely target BCR-ABL and related kinase pathways can help improve treatment effects, delay disease progression, and provide follow-up treatment options when drug resistance occurs.

In general, bosutinib mainly targets the BCR-ABL fusion gene, while also taking into account SRC family kinases, and achieves anti-tumor effects by intervening in the core driving signals of leukemia cells. This multi-target feature not only enhances the efficacy of the drug, but also provides more clinical options. Especially in the face of drug-resistant or relapsed patients, the importance of bosutinib as a targeted drug has become increasingly prominent.

Reference materials:https://go.drugbank.com/drugs/DB06616